AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6591741
Drug: metrizoate 200
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metrizoate 200 mg I/ml
Trial: 6591741
Drug: iohexol 240
RxNorm normalized name: iohexol 240 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol 240 mg I/ml and iohexol 300 mg I/ml
Trial: 22198776
Drug: Diclofenac 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 100 mg rectally 30 to 60 minutes before ERCP plus somatostatin 0.25 mg/h for 6 hours
Trial: 22198776
Drug: Placebo suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppository and saline solution
Trial: 21034824
Drug: Recombinant adenovirus
RxNorm normalized name: Adenovirus/PNP
DrugBank: Adenovirus/PNP (DB17175)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant adenovirus serotype 5 (rAd5) vaccine encoding the envelope glycoprotein (GP) from the Zaire and Sudan Ebola virus species, administered at 2×10(9) viral particles (n=12)
Trial: 21034824
Drug: Recombinant adenovirus
RxNorm normalized name: Adenovirus/PNP
DrugBank: Adenovirus/PNP (DB17175)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant adenovirus serotype 5 (rAd5) vaccine encoding the envelope glycoprotein (GP) from the Zaire and Sudan Ebola virus species, administered at 2×10(10) viral particles (n=11)
Trial: 9661803
Drug: Temocapril, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temocapril, 2 to 4 mg once daily for 12 months
Trial: 11131271
Drug: Diuretic (trichlormethiazide)
RxNorm normalized name: Trichlormethiazide
DrugBank: Trichlormethiazide (DB01021)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diuretic (trichlormethiazide) continued for an additional 12 months
Trial: 8825539
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration with lidocaine 1% with adrenaline 1:200,000, 0.4 ml.kg‐1 (n = 21)
Trial: 8825539
Drug: Nerve blockade
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve blockade with bupivacaine 0.5%, 0.4 ml.kg‐1 (n = 22)
Trial: 2990260
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received the same drugs (droperidol, flunitrazepam, pancuronium, nitrous oxide with oxygen)
Trial: 29063860
Drug: Voxilaprevir (VOX)
DrugBank: Voxilaprevir (DB12026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voxilaprevir (VOX) 100 mg
Trial: 25223172
Drug: Kuntai Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kuntai Capsule (KC)
Trial: 17679728
Drug: Anastrozole 1
RxNorm normalized name: anastrozole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg daily for 16 weeks + gefitinib 250 mg/d orally for 16 weeks
Trial: 17679728
Drug: Anastrozole 1
RxNorm normalized name: anastrozole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg daily for 16 weeks
Trial: 10190536
Drug: Alternate-day simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alternate-day simvastatin and fenofibrate therapy
Trial: 10190536
Drug: Standard daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard daily combination of simvastatin and fenofibrate
Trial: 7799040
Drug: Very low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Very low-dose warfarin (VLDW)
Trial: 28060040
Drug: Cysticidal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysticidal therapy
Trial: 25962515
Drug: OPTIMAL (occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPTIMAL (occupational therapy led self-management support programme)
Trial: 22185865
Drug: Low-dose multidetector
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose multidetector computed tomography (CT) screening
Trial: 15310780
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo or no therapy)
Trial: 11497229
Drug: New cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New cytotoxic drugs (vinorelbine, paclitaxel, docetaxel, gemcitabine, irinotecan)
Trial: 11497229
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cisplatin and newer drugs
Trial: 11497229
Drug: Docetaxel and
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel and other newer drugs
Trial: 11497229
Drug: Newer drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer drug combinations
Trial: 9462204
Drug: LAC (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAC (30 mg of lansoprazole twice daily + 1 g of amoxycillin twice daily + 400 mg of metronidazole twice daily)
Trial: 9462204
Drug: LAM (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAM (30 mg of lansoprazole twice daily + 1 g of amoxycillin twice daily + 250 mg of clarithromycin twice daily)
Trial: 9462204
Drug: LCM (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCM (30 mg of lansoprazole twice daily + 400 mg of metronidazole twice daily + 250 mg of clarithromycin twice daily)
Trial: 9462204
Drug: OAM (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAM (20 mg of omeprazole twice daily + 1 g of amoxycillin twice daily + 400 mg of metronidazole twice daily)
Trial: 22151836
Drug: Mealtime insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mealtime insulin aspart
Trial: 30487974
Drug: Bedtime insulin
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime insulin detemir
Trial: 25537011
Drug: Tideglusib 1000
RxNorm normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tideglusib 1000 mg QD
Trial: 25537011
Drug: Tideglusib 1000
RxNorm normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tideglusib 1000 mg QOD
Trial: 25537011
Drug: Tideglusib 500
RxNorm normalized name: Tideglusib
DrugBank: Tideglusib (DB12129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tideglusib 500 mg QD
Trial: 23522973
Drug: Radionuclide therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radionuclide therapy (Samarium‐153 EDTMP), N=12
Trial: 23522973
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no radionuclide therapy), N=12
Trial: 20693354
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart administered 15 min before mealtime
Trial: 12826500
Drug: Captopril (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (administered 8 hours and 1 hour before coronary angiography)
Trial: 12826500
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no captopril treatment)
Trial: 11196396
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg/day for 1 week, increased to 40 mg/day for the following weeks
Trial: 11196396
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg/day plus local application of lidocaine ointment
Trial: 11196396
Drug: Fluoxetine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine plus lidocaine ointment
Trial: 8992100
Drug: Cefixime 8
RxNorm normalized name: cefixime 8 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime 8 mg/kg bodyweight once daily for 5 days
Trial: 24755906
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg three times a day for 3 days)
Trial: 20586522
Drug: Pregabalin (300,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (300, 450, and 600 mg daily)
Trial: 18852414
Drug: IVT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVT treatment followed by PDT
Trial: 17058733
Drug: 2-liter electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-liter electrolyte lavage solution plus 20 mg of oral bisacodyl
Trial: 7488484
Drug: vecuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vecuronium 0.1 mg kg‐1
Trial: 8739020
Drug: Intravenous quinaprilat
RxNorm normalized name: quinaprilat
DrugBank: Quinaprilat (DB14217)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous quinaprilat 0.5 mg
Trial: 8739020
Drug: Intravenous quinaprilat
RxNorm normalized name: quinaprilat
DrugBank: Quinaprilat (DB14217)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous quinaprilat 1.0 mg and higher
Trial: 10024837
Drug: Intravenous quinaprilat
RxNorm normalized name: quinaprilat
DrugBank: Quinaprilat (DB14217)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous quinaprilat
Trial: 8739020
Drug: Intravenous quinaprilat
RxNorm normalized name: quinaprilat
DrugBank: Quinaprilat (DB14217)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous quinaprilat 2.5 mg
Trial: 8739020
Drug: Intravenous quinaprilat
RxNorm normalized name: quinaprilat
DrugBank: Quinaprilat (DB14217)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous quinaprilat 10 mg
Trial: 8739020
Drug: Oral quinapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral quinapril 20 mg
Trial: 8739020
Drug: Intravenous quinaprilat
RxNorm normalized name: quinaprilat
DrugBank: Quinaprilat (DB14217)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous quinaprilat 10 mg and oral quinapril 20 mg
Trial: 6352533
Drug: 3% undecylenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% undecylenic acid and its zinc salt cream
Trial: 30015785
Drug: Child‐ and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child‐ and Family‐focused Cognitive‐Behavioral Therapy (CFF‐CBT)
Trial: 28112799
Drug: Oxymatrine (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymatrine (0.6 g per day for 8 weeks)
Trial: 28112799
Drug: Acitretin (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acitretin (0.75 mg kg‐1 per day from week 0 to week 2 and 20‐30 mg per day from week 3 to week 8)
Trial: 18398801
Drug: Augmentation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation with atypical antipsychotics (AAP), particularly olanzapine; specific dosage and duration not mentioned.
Trial: 18398801
Drug: Augmentation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation with atypical antipsychotics (AAP); specific dosage and duration not mentioned.
Trial: 15117040
Drug: Topical ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ciprofloxacin 0.3%
Trial: 11201778
Drug: Topical ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ofloxacin 0.3%
Trial: 11400186
Drug: (R)‐carvedilol 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (R)‐carvedilol 12.5 mg
Trial: 11400186
Drug: (S)‐carvedilol 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (S)‐carvedilol 12.5 mg
Trial: 11400186
Drug: (R,S)‐carvedilol 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (R,S)‐carvedilol 25 mg
Trial: 9257784
Drug: mSRW (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mSRW (high doses >20 microg of Amb a 1)
Trial: 8292063
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg dimetindene
Trial: 8292063
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg dimetindene
Trial: 23991622
Drug: Prasugrel (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (30 mg loading dose before angiography, additional 30 mg at PCI if indicated)
Trial: 21414048
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy (OIT) with gradual updosing to 800 mg of protein (5 peanuts/day) followed by 30-week maintenance
Trial: 21414048
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy (OIT) with gradual updosing
Trial: 18806534
Drug: Topical fentanyl
RxNorm normalized name: fentanyl Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fentanyl plus dexpanthenol
Trial: 10995003
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (1.5 g/m2, 2.25 g/m2, or 3 g/m2 every 2 weeks for three doses)
Trial: 10995003
Drug: Fludarabine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine (25 mg/m2/day for 5 days every 4 weeks for six cycles)
Trial: 10995003
Drug: Fludarabine followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine followed by high-dose cyclophosphamide
Trial: 20549501
Drug: Meloxicam 7.5
RxNorm normalized name: meloxicam 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam 7.5 mg once daily
Trial: 8981385
Drug: Scopolamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (0.5 mg i.v.)
Trial: 3849459
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Pancreatin and Cimetidine
Trial: 3849459
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (previous studies)
Trial: 17012980
Drug: Adjunctive quetiapine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive quetiapine (<400 mg/day)
Trial: 16239629
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin therapy
Trial: 16239629
Drug: Low-dose vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vitamin therapy
Trial: 8965152
Drug: Acetaminophen with
RxNorm normalized name: acetaminophen with codeine ORAL ELIXIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen with codeine (APAP/C)
Trial: 1464159
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) treatment during intensive consolidation
Trial: 1464159
Drug: Folate (F)
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folate (F) levels during treatment
Trial: 1464159
Drug: RBC MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC MTX and RBC F levels during maintenance therapy
Trial: 31738483
Drug: Lower-target group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-target group (LDL cholesterol < 70 mg/dL)
Trial: 31738483
Drug: Higher-target group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-target group (LDL cholesterol 90-110 mg/dL)
Trial: 26084138
Drug: Tramadol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (1.5 mg/kg loading dose and patient-controlled analgesia for 1 day)
Trial: 26084138
Drug: Paracetamol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1 g intravenously 30 min before the end of the operation and 1 g each day at 6‐h intervals)
Trial: 18632258
Drug: Budesonide plus
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide plus formoterol (400 mcg and 24 mcg/day, respectively)
Trial: 18632258
Drug: Budesonide (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (800 mcg/day)
Trial: 11125148
Drug: Cholinesterase inhibitor
RxNorm normalized name: Acetylcholinesterase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinesterase inhibitor physostigmine
Trial: 9013229
Drug: Treatment according
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment according to protocol
Trial: 1575333
Drug: Propofol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2.5 mg/kg and 1.0 mg/kg 3 min later)
Trial: 1575333
Drug: Thiopental (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (5.0 mg/kg and 2.0 mg/kg 3 min later)
Trial: 31939265
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) applied perineally, 3000 pulses weekly for four consecutive weeks, energy flux density 0.25 mJ/mm2, frequency 4 Hz
Trial: 31939265
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment with a non-functional handpiece
Trial: 27526146
Drug: BioPQQ™ (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BioPQQ™ (20 mg)
Trial: 24429126
Drug: QVA149 (indacaterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 (indacaterol 110 μg and glycopyrronium 50 μg)
Trial: 24429126
Drug: Glycopyrronium (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium (50 μg)
Trial: 23558666
Drug: Tiotropium (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (18 μg)
Trial: 19589894
Drug: Etoricoxib 30
RxNorm normalized name: Etoricoxib 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 30 mg
Trial: 21905970
Drug: Etoricoxib 60
RxNorm normalized name: etoricoxib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 60 mg and 90 mg
Trial: 1743317
Drug: 0.1‐mg Estraderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1‐mg Estraderm Patch worn for 7 days with 0.6 mL of ethanol injected on day 3
Trial: 1743317
Drug: 0.1‐mg Estraderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1‐mg Estraderm Patch worn for 7 days without ethanol
Trial: 6292957
Drug: Trimethoprim-polymyxin ophthalmic
RxNorm normalized name: polymyxin B / trimethoprim Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-polymyxin ophthalmic solution
Trial: 6292957
Drug: Chloramphenicol ophthalmic
RxNorm normalized name: chloramphenicol ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramphenicol ophthalmic solution
Trial: 31928864
Drug: Cerebellar rTMS
RxNorm normalized name: Sus scrofa cerebellum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebellar rTMS (10Hz, 250 pulse) - single treatment
Trial: 31928864
Drug: Cerebellar rTMS
RxNorm normalized name: Sus scrofa cerebellum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebellar rTMS - daily for 3 days, twice-daily for 5 days
Trial: 31928864
Drug: Sham stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham stimulation - twice-daily for 5 days
Trial: 28626140
Drug: LCPUFA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCPUFA supplementation (docosahexaenoic acid (DHA) 300 mg/day, eicosapentaenoic acid (EPA) 100 mg/day, arachidonic acid (ARA) 120 mg/day)
Trial: 18710719
Drug: Placebo (folic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (folic acid tablets)
Trial: 15985034
Drug: 4% hydroquinone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% hydroquinone cream (group A)
Trial: 15985034
Drug: 4% hydroquinone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% hydroquinone, 0.05% tretinoin and 0.05% dexamethasone cream (group B)
Trial: 11928798
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality therapy for rectal cancer
Trial: 2187603
Drug: Solution A
RxNorm normalized name: I.V. SOLUTION ADDITIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution A (168 mmol/L sugar, 326 mosm/kg)
Trial: 2187603
Drug: Solution D
RxNorm normalized name: KIT, PATCH, MEDICATED AND SOLUTION DROPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution D (90 mmol/L sugar, 240 mosm/kg)
Trial: 6103680
Drug: Timolol maleate
RxNorm normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol maleate 10 to 30 mg per day
Trial: 31236874
Drug: Treatment-related increases
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-related increases in dietary restraint behaviors
Trial: 26003406
Drug: Usual daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual daily activities (control group).
Trial: 19174530
Drug: LC-MS/MS steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC-MS/MS steroid measurements
Trial: 6148879
Drug: Propranolol, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol, 40 mg every 6 hours for 14 days
Trial: 6148879
Drug: Nadolol, 80
RxNorm normalized name: Nadolol, 80 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol, 80 mg each morning for 14 days
Trial: 27146108
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (Crinone 8% vaginal gel, 90 mg per day) for 14 days in CC/IUI cycles
Trial: 27146108
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (Crinone 8% vaginal gel, 90 mg per day) for 14 days in Gn/IUI cycles